Durvalumab Brand Name– IMFINZI
What is Durvalumab
Durvalumab is a human IgG1 kappa monoclonal antibody that binds to and blocks programmed death-ligand 1 (PD-L1).
It is approved as monotherapy for the treatment of patients with locally advanced or metastatic urothelial carcinoma as well as patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemoradiotherapy.
It is also approved in combination with etoposide and either cisplatin or carboplatin for the first-line treatment of extensive-stage small cell lung cancer.
Immune-mediated adverse reactions including colitis, pneumonitis, hepatitis, endocrinopathies, and nephritis have been reported with durvalumab therapy in clinical trials; treatment with high-dose corticosteroids may be necessary in patients who develop immune-mediated toxicity. Severe infusion-related reactions may also occur
Indications
- non-small cell lung cancer (NSCLC)
- small cell lung cancer (SCLC)
- urothelial carcinoma
For the treatment of urothelial carcinoma
for the treatment of locally advanced or metastatic urothelial carcinoma, in patients with disease progression on or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
Side Effects
- abdominal pain
- acneiform rash
- adrenocortical insufficiency
- alopecia
- anemia
- anorexia
- antibody formation
- aseptic meningitis
- asthenia
- back pain
- bullous rash
- colitis
- constipation
- cough
- cystitis
- dehydration
- diabetes insipidus
- diabetes mellitus
- diarrhea
- dysphonia
- dyspnea
- dysuria
- edema
- elevated hepatic enzymes
- erythema
- erythema multiforme
- fatigue
- fever
- flank pain
- glomerulonephritis
- Guillain-Barre syndrome
- hemolytic anemia
- hepatitis
- hepatotoxicity
- hyperbilirubinemia
- hypercalcemia
- hyperglycemia
- hyperkalemia
- hypermagnesemia
- hyperthyroidism
- hypoalbuminemia
- hypocalcemia
- hypokalemia
- hyponatremia
- hypophysitis
- hypopituitarism
- hypothyroidism
- ileus
- infection
- infusion-related reactions
- interstitial nephritis
- iritis
- keratitis
- laryngitis
- lethargy
- lichen planus-like eruption
- lymphopenia
- maculopapular rash
- malaise
- musculoskeletal pain
- myalgia
- myasthenia gravis
- myocarditis
- nausea
- neutropenia
- night sweats
- ocular inflammation
- pancreatitis
- paresis
- peripheral edema
- pharyngitis
- pneumonitis
- pneumonitis
- pruritus
- psoriaform rash
- psoriasis
- pulmonary fibrosis
- purpura
- rash
- renal failure (unspecified)
- rhabdomyolysis
- rhinitis
- sinusitis
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- uveitis
- vasculitis
- Vogt-Koyanagi-Harada syndrome
- vomiting
Monitoring Parameters
- blood glucose
- LFTs
- serum creatinine/BUN
- thyroid function tests (TFTs)
Contraindications
- adrenal insufficiency
- aseptic meningitis
- autoimmune disease
- breast-feeding
- colitis
- contraception requirements
- Crohn’s disease
- diabetes mellitus
- diarrhea
- hemolytic anemia
- hepatic disease
- hepatitis
- hyperthyroidism
- hypophysitis
- hypopituitarism
- hypothyroidism
- immune-mediated reactions
- immunosuppression
- inflammatory bowel disease
- infusion-related reactions
- keratitis
- myocarditis
- organ transplant
- pneumonitis
- pregnancy
- pulmonary disease
- renal disease
- renal impairment
- reproductive risk
- serious rash
- systemic lupus erythematosus (SLE)
- thyroid disease
- type 1 diabetes mellitus
- ulcerative colitis
- uveitis
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
